Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.
Bottom Line:
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections.It is currently in phase III development with promising results so far.This review looks at the development history and scientific profile of this drug to date.
View Article:
PubMed Central - PubMed
ABSTRACT
Show MeSH
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date. Related in: MedlinePlus |
![]() Related In:
Results -
Collection
getmorefigures.php?uid=PMC3585687&req=5
Tab1: Features and properties |
View Article: PubMed Central - PubMed